|
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II
|
Nov 2016
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide
|
May 2014
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Multiparameter FLAER-based flow cytometry for screening of paroxysmal nocturnal hemoglobinuria enhances detection rates in patients with aplastic anemia
|
Dec 2014
|
Ann Hematol
|
aplastic anemia
|
|
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
|
Apr 2014
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Efficacy and safety of deferasirox in myelodysplastic syndromes
|
Feb 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol
|
Aug 2016
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
|
Oct 2015
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
|
Jul 2012
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
|
Jun 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia
|
Aug 2017
|
Ann Hematol
|
aplastic anemia
|
